S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
Urgent Warning (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
Urgent Warning (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Urgent Warning (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
NASDAQ:PRTK

Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News

$1.65
-0.04 (-2.37%)
(As of 03/24/2023 08:51 PM ET)
Add
Compare
Today's Range
$1.62
$1.71
50-Day Range
$1.37
$2.40
52-Week Range
$1.29
$3.65
Volume
465,000 shs
Average Volume
485,104 shs
Market Capitalization
$94.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Paratek Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
1,112.1% Upside
$20.00 Price Target
Short Interest
Bearish
7.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.98
Upright™ Environmental Score
News Sentiment
-0.26mentions of Paratek Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$13,300 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.97) to $0.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.12 out of 5 stars

Medical Sector

985th out of 1,005 stocks

Pharmaceutical Preparations Industry

475th out of 486 stocks


PRTK stock logo

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Stock News Headlines

My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
Q4 2022 Paratek Pharmaceuticals Inc Earnings Call
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Why Paratek Pharmaceuticals Stock Is Plunging Today
Paratek Pharmaceuticals Earnings Preview
See More Headlines
Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Company Calendar

Last Earnings
11/08/2021
Today
3/26/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CUSIP
89354M10
Employees
207
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$20.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+506.1%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-63,570,000.00
Pretax Margin
-39.63%

Debt

Sales & Book Value

Annual Sales
$160.27 million
Book Value
($3.08) per share

Miscellaneous

Free Float
52,684,000
Market Cap
$94.48 million
Optionable
Optionable
Beta
1.52

Social Links


Key Executives

  • Evan LohEvan Loh
    Chief Executive Officer & Director
  • Adam WoodrowAdam Woodrow
    President & Chief Commercial Officer
  • Sarah Higgins
    VP, Chief Financial & Accounting Officer
  • Raj Padmanabhan
    Vice President-Information Technology
  • Paul McGovern
    Vice President-Clinical & Medical Affairs













PRTK Stock - Frequently Asked Questions

What is Paratek Pharmaceuticals' stock price forecast for 2023?

0 equities research analysts have issued 1 year price objectives for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $10.00 to $30.00. On average, they expect the company's share price to reach $20.00 in the next year. This suggests a possible upside of 1,112.1% from the stock's current price.
View analysts price targets for PRTK
or view top-rated stocks among Wall Street analysts.

How have PRTK shares performed in 2023?

Paratek Pharmaceuticals' stock was trading at $1.87 at the beginning of the year. Since then, PRTK shares have decreased by 11.8% and is now trading at $1.65.
View the best growth stocks for 2023 here
.

When is Paratek Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our PRTK earnings forecast
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its quarterly earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to the consensus estimate of $22.98 million. During the same quarter in the prior year, the business earned ($0.46) earnings per share.

What ETFs hold Paratek Pharmaceuticals' stock?

ETFs with the largest weight of Paratek Pharmaceuticals (NASDAQ:PRTK) stock in their portfolio include AltShares Event-Driven ET (EVNT) and Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM).

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, March, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $143.00 million-$158.00 million, compared to the consensus revenue estimate of $232.02 million.

What other stocks do shareholders of Paratek Pharmaceuticals own?
What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include AIGH Capital Management LLC (7.48%), General American Investors Co. Inc. (3.39%), Millennium Management LLC (1.02%), Geode Capital Management LLC (0.84%), CM Management LLC (0.62%) and Renaissance Technologies LLC (0.44%). Insiders that own company stock include Adam Woodrow, Evan Loh, Jeffrey Stein, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends
.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $1.65.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $94.48 million and generates $160.27 million in revenue each year. The specialty pharmaceutical company earns $-63,570,000.00 in net income (profit) each year or ($1.18) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

The company employs 207 workers across the globe.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.

This page (NASDAQ:PRTK) was last updated on 3/27/2023 by MarketBeat.com Staff